Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (the "Company") reports material events occurring on November 4, 2021. The Company is a Delaware corporation focused on regenerative medicine, specifically clinical trials for BRTX-100 and pre-clinical research for its ThermoStem Program.
Key Financial Metrics and Capital Structure
Capital Raise: The Company entered into an underwriting agreement to sell 2,300,000 units at $10.00 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock.
Over-Allotment: On November 5, 2021, underwriters exercised an option to purchase warrants for an additional 345,000 shares.
Net Proceeds: Approximately $20,869,000 after deducting underwriting discounts, commissions, and offering expenses.
Use of Proceeds: Funds are designated for clinical trials of BRTX-100, pre-clinical R&D for the ThermoStem Program, and general corporate working capital.
Warrant Terms: Exercise price of $10.00 per share; exercisable immediately; expire five years from issuance.
Note: This filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes and Corporate Actions
- Executive Appointment: Robert E. Kristal was appointed Chief Financial Officer effective November 4, 2021.
- Board Elections: Patrick F. Williams and David Rosa were elected as directors effective November 4, 2021. Mr. Williams was appointed Chair of the Audit Committee, and Mr. Rosa was appointed Chair of the Nominating Committee.
- Stock Option Grants: Options were granted to officers and directors for a total of 140,824 shares at an exercise price of $13.50 per share. Key grants include 42,059 shares each to Lance Alstodt and Francisco Silva.
- Option Price Reduction: The exercise price for existing options held by Messrs. Alstodt and Silva (covering 293,479 shares each) was reduced from $47.60 to $13.50 per share.
Outlook, Risks, and Management Commentary
The Company intends to utilize the net proceeds to advance its clinical and pre-clinical development pipelines. The offering is expected to close on November 9, 2021, subject to customary closing conditions. The filing references a press release issued on November 4, 2021, regarding the pricing of the offering, which is furnished but not filed as part of this report.
Risks/Contingencies: The closing of the offering is subject to customary conditions. The reduction in exercise price for existing options may have accounting implications not detailed in this summary.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received from the offering.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Confirm the impact of the stock option price reduction on the Company's financial statements and potential dilution.
- Monitor the progress of clinical trials for BRTX-100 and the ThermoStem Program as funded by the new capital.
- Check for any subsequent filings regarding the exercise of the remaining over-allotment option for common stock shares.